Data from preclinical in vitro studies have shown the effectiveness of sorafenib (a pan-TKI) in T-ALL cell lines transfected with FLT3-ITD and FLT3-wt constructs [41]. Here, FLT3 is linked to acute lymphoblastic leukemia.